TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04526626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation for treatment of lower limb varicose veins (ClosureFast, Medtronic)
Description: Thermal injury to long saphenous vein
Study: NCT04053166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: individualized home-based physical activity
Description: Subjects will have to reach a daily goal in number of steps, based on the initial evaluation, during 6 months . They will wear connected wrists, and will be contacted twice a month by phone call by an adapted physical activity to revaluate these goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: An MRI will be performed for each patient at the end of the study to identify IPH and other features of histological vulnerability (lipid core, fibrous cap integrity and calcifications).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: An MRI will be performed for each patient at the end of the study to identify IPH and other features of histological vulnerability (lipid core, fibrous cap integrity and calcifications).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling
Description: Blood will be collected, to analyse monocyte phenotype by flow cytometry, blood rheology by ektacytometry, coagulation by rotational thromboelastometry (ROTEM). Plasma will be extracted from blood to assess inflammation, oxidative stress and antioxidant markers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Blood will be collected, to analyse monocyte phenotype by flow cytometry, blood rheology by ektacytometry, coagulation by rotational thromboelastometry (ROTEM). Plasma will be extracted from blood to assess inflammation, oxidative stress and antioxidant markers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: sedentary, physical activity, nutrition and quality of life questionnaire will be performed fo each patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: sedentary, physical activity, nutrition and quality of life questionnaire will be performed fo each patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-minute walk test
Description: The 6-minute walk test is a simple, individualized test that measures how fast a patient walks on a flat, hard surface for 6 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: The 6-minute walk test is a simple, individualized test that measures how fast a patient walks on a flat, hard surface for 6 minutes.
Study: NCT04051853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be gradually escalated up to 400 mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be gradually escalated up to 400 mg BID.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Midazolam clearance test
Description: Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP cocktail clearance test
Description: In a subgroup of 15 patients (in the Academic Medical Center Amsterdam), this test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.
Study: NCT02566317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sit-Stand workstation
Description: Installation of a sit-stand desk at work

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Move
Description: A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move
Description: A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace
Study: NCT02842164

Intervention type: OTHER
Group type: OTHER
Intervention: Tension group

Intervention type: OTHER
Group type: OTHER
Intervention: No tension group

Intervention type: OTHER
Group type: OTHER
Intervention: Foley catheter Balloon

Intervention type: OTHER
Group type: OTHER
Intervention: Foley catheter Balloon
Study: NCT04017091

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Training
Description: Bimodal VR-Stroop (ClinicaVR: Apartment Stroop) Patient find themselves seated with a virtual apartment, where they see a living room, in front of a flat-screen TV set, a kitchen and a window. This intervention consisted of two Stroop conditions across all 8 sessions. In Condition 1 (Inhibition), Patients indicated when the color named (audio stimulus) matched the color shown (visual stimulus). Participants were to withhold their response in mismatched trials. In Condition 2 (Interference), Participants clicked the mouse when the color heard was the same as the ink color; not the word printed.
Study: NCT03634163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neighbourhood exchange
Description: Facilitated coaching support to identify needs and priorities and link with resources - personal, community, friend and family, or from professional service providers; plan and implement a personalized care pathway through community exchange

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Assessment
Description: Completion of baseline measures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Completion of baseline measures
Study: NCT04292730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study: NCT04565054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 50 MG; 150mg 1-0-1 per os
Description: Experimental: Abemaciclib plus ET Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
Study: NCT00969553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: Dose level 1
Study: NCT01393743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Study: NCT02529384

Intervention type: OTHER
Intervention: Breast magnetic resonance scanning
Description: Just a muti-b value series in breast MRI

Intervention type: OTHER
Intervention: Breast magnetic resonance scanning
Description: Just a muti-b value series in breast MRI

Intervention type: OTHER
Intervention: Breast magnetic resonance scanning
Description: Just a muti-b value series in breast MRI
Study: NCT03400033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat tablets
Description: Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo tablets
Description: Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa vials
Description: Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
Study: NCT01497860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
Study: NCT02038699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
Study: NCT03400033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline vials or bags
Description: 0.9% sodium chloride saline vials or bags administered by the IV route.
Study: NCT02443532

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individual education
Description: Usual care (individual consultations as routinely performed)
Study: NCT02296814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinusitis Hevert SL Tablet
Description: 1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Sinusitis Hevert SL Tablet
Description: 1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
Study: NCT01622946

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: 3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
Study: NCT03873376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-in; Receive offer to order self-sampling kit
Description: Women in the opt-in arm receive an offer to order a HPV self-sampling kit, in addition to information about the study. Women who order, receive a kit that includes a self-sampling brush (Evalyn, Rovers Medical Devices), with instructions for use and a pre-paid envelope for returning the brush for HPV testing. The women are also informed that they can attend ordinary screening, i.e. performed by a physician. Women who choose self-sampling and test positive for high-risk HPV will be 1:1 allocated to follow-up by their general practitioner or a gynecologist. Women who test negative for high-risk HPV return to the ordinary screening program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out; Receive self-sampling kit unsolicited
Description: Women in the opt-out arm receive the self-sampling kit directly, without having ordered it themselves. The kit has the same contents, and the follow-up is the same, as that described for the opt-in arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control; Receive open reminder to be screened by physician
Description: Similar to the procedure of the national screening program, women in the control arm receive a reminder to be screened by their general practitioner, and continues in the ordinary screening program
Study: NCT01506505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular Agents
Description: Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
Study: NCT01622946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
Study: NCT02061293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Study: NCT02613533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-ocular pressure measurement (IOP)
Description: Subjects will be given 10ml/kg of water over 15 min prior to laser peripheral iridotomy (LPI) surgery and Intra-ocular pressure (IOP) is tested every 15 min before and after surgical procedure
Study: NCT01506505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiovascular Agents
Description: Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiovascular Agents
Description: Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
Study: NCT01247090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin - Very Low Dose
Description: Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU \* 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin - Low Dose
Description: Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU \* 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
Study: NCT01690390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib of routine dose
Description: Icotinib of routine dose: 125 mg is administered orally three times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib of high dose
Description: Icotinib: 250 mg is administered orally three times per day.
Study: NCT02794272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-tDCS
Study: NCT04113473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: An hour of yoga therapy included loosening exercise (sukshma vyayama), yoga postures (asana), yoga breathing (pranayama), relaxation (shavasana) and meditation.~Each participant were given handouts to follow home practice sessions everyday for twice a day for at least 15 minutes.
Study: NCT03552510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oro-pharyngeal Administration of Mother's Milk
Description: Infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oro-pharyngeal Administration of Mother's Milk
Description: Infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding)
Study: NCT02901938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cemented femoral stem
Description: The patients assigned even numbers will undergo implantation of cemented femoral stem.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cannulated compression screws
Description: The patients assigned even numbers will undergo percutaneous internal fixation with cannulated compression screws.
Study: NCT01608100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARCHITECT STAT High Sensitive Troponin I Assay
Description: Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.~Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit.
Study: NCT02570464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood drawn
Description: Blood drawn is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Blood drawn
Description: Blood drawn is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
Study: NCT03304925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting machine will be used to perform the treatments.
Study: NCT00755742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided.
Study: NCT01385124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cannabidiol
Description: Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
Study: NCT00755742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided.
Study: NCT02684227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT00755742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided.
Study: NCT03832686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Coach
Description: The smartphone application, tailored to patients with HNC, will monitor patient progress while also providing a direct line to health care providers should any questions or concerns arise concerning their treatment. The mobile application will also feature instructional videos that describe the swallowing exercises in detail, providing patients with another resource to help improve their overall rehabilitation experience. Finally, home practice reminders and prompts will be used to help patients integrate the exercises into their daily routine.
Study: NCT01934439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 PAAD treatments
Description: Subjects will don a shirt with pockets at the elbow and shoulder in each of which a muscle vibrator is located. The subject will then place the affected arm in the PAAD. The PAAD will range the affected arm, at the shoulder in the adduction-abduction direction, and at the elbow in the flexion-extension direction. The subject will assist volitionally this motion, and visual feedback of the level of their assistive torque will be provided along with a target torque level. The muscle vibrators will alternate from one side of each of the 2 joints to the other as the motion reverses, vibration always being applied to the lengthening muscles. This treatment will last 30 min in each session.
Study: NCT01483443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oophrectomy
Description: Both oophrectomy
Study: NCT02684227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01209910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Subjects in this arm will be able to drink water with some conditions.